Evidence map›Paper›PMID 33029949›Full record

ArticleCancer reports (Hoboken, N.J.)2021

Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy.

Parmod Kumar, Deepak Sundriyal, Rekha Bhandari, Abhijeet Singh, Bhinyaram Jat, Amit Sehrawat

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Parmod KumarDepartment of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Deepak SundriyalDepartment of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.ORCID 0000-0002-6378-7694
Rekha BhandariDepartment of Pathology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Abhijeet SinghDepartment of Head and Neck Surgery, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Bhinyaram JatDepartment of Head and Neck Surgery, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Amit SehrawatDepartment of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.ORCID 0000-0001-7100-8999
All India Institute of Medical Sciences Rishikesh · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlfactory neuroblastoma (ONB) is a sinonasal malignancy seldom seen in clinical practice. It is also known by various other names like esthesioneuroblastoma, esthesioneuroepithelioma, esthesioneurocytoma, and esthesioneuroma. Surgery and radiation therapy are considered as standard treatment modalities for ONB; however, the role of chemotherapy is not well established.

aimsWe aim to define the role of chemotherapy in the neoadjuvant setting in a case of ONB. METHODS AND

resultsWe report a young female patient presenting with a naso-facial swelling causing facial disfigurement, proptosis, decreased visual acuity, and poor performance status. She was diagnosed with advanced-stage ONB. Prompt administration of chemotherapy led to the improvement in the symptoms and rapid regression of the tumor mass. Later on, the tumor mass was excised completely without any neurological deficit.

conclusionThis report justifies the role of neoadjuvant chemotherapy in the management of ONB.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBeautyCisplatinDepressionDiagnosis, DifferentialEsthesioneuroblastoma, OlfactoryEtoposideFaceFemaleHumansMagnetic Resonance ImagingNasal CavityNasal Surgical ProceduresNeoadjuvant TherapyNose Deformities, AcquiredCisplatinEtoposidechemosensitiveneoadjuvant chemotherapyolfactory neuroblastoma

Identifiers

PMID33029949
PMCPMC7941440
OpenAlexW3091886667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.